Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | S1PR1 | P21453 | 5/20 | 0.43 |
| ▸ | S1PR3 | Q99500 | 4/20 | 0.43 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.40 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6326921 | 0.90 | BLM (0.49) | RXFP1RAB9ALMNABLMALDH1A1 | |
| SCHEMBL6445482 | 0.89 | MAPT (0.47) | RXFP1RAB9AMAPTLMNABLM | |
| SCHEMBL6325733 | 0.89 | BLM (0.46) | RXFP1RAB9AMAPTS1PR1S1PR3 | |
| SCHEMBL6448516 | 0.87 | MAPT (0.45) | RXFP1RAB9AMAPTS1PR3BLM | |
| SCHEMBL6447047 | 0.85 | KDM4E (0.41) | RAB9AMAPTLMNABLMALDH1A1 | |
| SCHEMBL6449271 | 0.84 | LMNA (0.45) | ROCK1MAPTLMNABLMALDH1A1 | |
| SCHEMBL6448563 | 0.84 | F10 (0.42) | RXFP1RAB9AMAPTLMNAALDH1A1 | |
| SCHEMBL6447202 | 0.84 | KMT2A (0.46) | RAB9AMAPTBLMKDM4EMAPK1 | |
| SCHEMBL6445978 | 0.83 | SNCA (0.47) | RXFP1RAB9ALMNAALDH1A1KDM4E | |
| SCHEMBL6444592 | 0.83 | RAB9A (0.46) | RXFP1RAB9AMAPTLMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050143384-A1 | Amide thiadiazole inhibitors of plasminogen activator inhibitor-1 | BRISTOL-MYERS SQUIBB COMPANY | 2005-06-30 | — | — | US | claimed |
| US-20050143384-A1 | Amide thiadiazole inhibitors of plasminogen activator inhibitor-1 | BRISTOL-MYERS SQUIBB COMPANY | 2005-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143384-A1 | Amide thiadiazole inhibitors of plasminogen activator inhibitor-1 | SERPINE1, SERPINC1, SERPINB1 | RXFP1 508/4885RAB9A 1792/4885ROCK1 885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.